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Abstract
Background: While increased urokinase-type plasminogen activator (uPA) expression in breast
cancer tissue is directly associated with poor prognosis, recent evidence suggests that uPA
overexpression may suppress tumor growth and prolong survival. Celecoxib has been shown to
have antiangiogenic and antiproliferative properties. We sought to determine if uPA, PA inhibitor
(PAI)-1 and prostaglandin (PG)E2 expression in nipple aspirate fluid (NAF) and uPA and PGE2
expression in plasma were altered by celecoxib dose and concentration in women at increased
breast cancer risk.
Methods: NAF and plasma samples were collected in women at increased breast cancer risk
before and 2 weeks after taking celecoxib 200 or 400 mg twice daily (bid). uPA, PAI-1 and PGE2
were measured before and after intervention.
Results: Celecoxib concentrations trended higher in women taking 400 mg (median 1025.0 ng/mL)
compared to 200 mg bid (median 227.3 ng/mL), and in post- (534.6 ng/mL) compared to
premenopausal (227.3 ng/mL) women. In postmenopausal women treated with the higher (400 mg
bid) celecoxib dose, uPA concentrations increased, while PAI-1 and PGE2 decreased. In women
taking the higher dose, both PAI-1 (r = -.97, p = .0048) and PGE2 (r = -.69, p = .019) in NAF and
uPA in plasma (r = .45, p = .023) were correlated with celecoxib concentrations.
Conclusion: Celecoxib concentrations after treatment correlate inversely with the change in PAI-
1 and PGE2 in the breast and directly with the change in uPA in the circulation. uPA upregulation,
in concert with PAI-1 and PGE2 downregulation, may have a cancer preventive effect.
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Background
Cancer cell invasion and metastasis requires the degrada-
tion of the extracellular matrix (ECM) and basement
membrane. This process is accomplished by several pro-
teins, including those of the plasminogen activator (PA)
system. Urokinase-type PA (uPA), which is secreted in
inactive form (pro-uPA), plays a key role in ECM degrada-
tion. Pro-uPA is converted to its active form after binding
to its specific surface receptor, uPAR [1,2]. In women with
breast cancer, uPA appears to promote cancer invasion
and metastasis [3] through degradation of the ECM, stim-
ulation of angiogenesis, alteration in cell migration and
adhesion [4], and inhibition of apoptosis [5].
The total involvement of plasminogen activators in can-
cer, however, is not that clear. In addition to demon-
strated negative effects, PAs apparently play a positive role
in certain aspects of the cancer process. For example, PAs
induce antiangiogenic activity in vitro and in patients with
cancer [6]. Several clinical studies have shown associa-
tions between high tissue-type PA expression and activity
and a favorable prognosis in breast cancer [7]. In a mouse
mammary cancer model, induced uPA expression delayed
tumor progression and had antiangiogenic and antiprolif-
erative effects. Tumors expressing proteolytically inactive
uPA mutants grew faster than tumors overexpressing pro-
teolytically active uPA, suggesting that the inhibitory
actions were mediated by uPA's protease activity [8].
Plasminogen activator activity is inhibited by plasmino-
gen activator inhibitor-1 (PAI-1) [9]. While uPA has both
positive and negative actions in cancer, PAI-1 promotes
breast cancer invasion and metastasis. Deficient PAI-1
expression in mice prevented local invasion and tumor
vascularization of transplanted malignant keratinocytes.
When PAI-1 expression was restored, invasion and associ-
ated angiogenesis were also restored, suggesting that host-
produced PAI-1 is essential for cancer cell invasion and
angiogenesis [10]. PAI-1 promotes angiogenesis by
directly inhibiting proteases [11], suggesting that exces-
sive plasmin proteolysis may prevent the assembly of
tumor blood vessels. Possible mechanisms by which PAI-
1 promotes breast cancer include prevention of excess
ECM degradation, modulation of cell adhesion, a role in
angiogenesis, and the stimulation of cell proliferation [3].
It therefore appears that the association of uPA and PAI-1
expression with breast cancer is complex.
Two hypotheses proposed for the effects of PAs on tumor
invasiveness [8] are that enhanced proteolytic activity of
uPA may result in cleavage of tumor stromal proteins into
peptides that inhibit angiogenesis and/or proliferation, or
that plasmin generated by uPA activity activates other
stromal proteases, leading to tumor matrix disruption.
Celecoxib is an anti-inflammatory agent known to have
antiangiogenic [12] and antiproliferative properties [13].
The agent has been shown to prevent [14] and treat mam-
mary tumors in animal models [15]. We observed that
celecoxib blocks prostaglandin (PG)E2  in high risk
women and in women with breast cancer [16]. Celecoxib
has been reported to inhibit uPA production in MDA-MB-
231 breast cancer cells [17].
We previously reported that PGE2, a small lipid associated
with breast tumor development, decreased in proportion
to circulating celecoxib concentration in postmenpausal
women taking the 400 mg twice daily (bid) dose [18]. Our
previous experience using celecoxib to inhibit eicosanoid
production, the fact that celecoxib affects uPA production
and the conflicting findings regarding the role of uPA and
PAI-1 in tumor progression caused us to investigate the
expression of uPA and PAI-1 in the breast and uPA system-
ically before and after treatment with low (200 mg bid)
and high (400 mg bid) dose celecoxib.
Methods
Subject recruitment
Between October 2001 and December 2004, women were
provided an Institutional Review Board approved proto-
col and required to give written informed consent in order
to enroll in the study. Subjects enrolled during the first
half of the study received 200 mg celecoxib bid, and those
enrolled during the second half received 400 mg bid. Sub-
jects evaluated had to be ≥ 18 years old and be at increased
breast cancer risk, based on the subject having either a
Gail model risk of developing IBC in a 5 year period of >
1.66%, or previously treated DCIS or IBC (now finished
with treatment and free of disease).
Pregnant and lactating women were not eligible. Women
could not have been currently on nonsteroidal antiin-
flammatory drugs (NSAIDs), a cyclo-oxygenase-2 (COX-
2) inhibitor, warfarin, or have taken such a medication
within two weeks of enrollment. Subjects could not have
a significant history of peptic ulcer disease, upper gas-
trointestinal bleeding, asthma, or be allergic to sulfona-
mides or NSAIDs. A complete blood count, serum
electrolytes and liver panel performed within two months
of enrollment had to be within normal limits. Subjects
were recruited from the breast evaluation clinics at the
University of Missouri-Columbia.
Intervention
Celecoxib pills were taken for 14 days. The treatment
period was chosen to be short enough to maximize com-
pliance yet long enough to see a biomarker effect, based
on celecoxib's half life of 11 hours. Compliance was
assessed through the count of returned pills. All subjectsBMC Cancer 2008, 8:298 http://www.biomedcentral.com/1471-2407/8/298
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were required to have taken at least 80% of the prescribed
medication.
Specimen collection
NAF was collected using a modified breast pump as previ-
ously described [19,20]. Briefly, the breast was warmed
with moist heated towels for 5–10 minutes, subsequently
massaged from the chest wall toward the nipple while a
health care professional provided suction using a modi-
fied breast pump. The sample was collected into capillary
tubes and stored at -80°C until analysis. NAF volume was
measured using a metric ruler. We have determined that
one mm in the tube corresponds to approximately one μL
of NAF. NAF was collected from only one breast, and NAF
from the same breast was analyzed before and after treat-
ment.
Baseline NAF and blood collection were performed prior
to the ingestion of celecoxib. Eight mL of blood were also
collected from the subject in a tube containing heparin,
the blood centrifuged for 10 min at 1600 rpm, and the
plasma fraction decanted and stored at -80°C until analy-
sis. All women had NAF and plasma collected within 24
hrs of their last dose of celecoxib, with an average of
approximately 12 hrs. The half life of the medication is
11.5 hrs.
Specimen analysis
uPA and PAI-1
uPA and PAI-1 enzyme linked immunosorbant assay kits
were obtained from American Diagnostica, Inc. (Stam-
ford, CT). uPA and uPAI-1 levels were determined accord-
ing to the kit manufacturer's instructions. Briefly, 100 μL
of standard and samples were pipetted into the microplate
wells that were coated with mouse monoclonal antibod-
ies respectively specific for uPA and PAI-1 and incubated
overnight at 4°C. A washing procedure was performed 4
times to remove unbound proteins with washing buffer.
Enzyme-linked antibodies specific for each factor were
added to the wells and incubated for 1 h at room temper-
ature. The wells were washed again, 100 μL diluted
enzyme conjugate (streptavidin conjugated horseradish
peroxidase) was pipetted into wells and incubated for 1 h
at room temperature, then washed again. Substrate rea-
gent (100 μL) was added to each well and incubated for 1
h at room temperature, followed by a stop solution (0.5 N
sulfuric acid). Absorbance values were measured at 450
nm for uPA and uPAI-1 using a microplate reader. The
detection limits were 10 pg/mL for uPA and 125 pg/mL
for PAI-1. To standardize uPA and PAI-1 expression in
NAF, total protein was measured for each sample with a
BCA protein assay kit (Pierce Chemicals, Rockford, IL),
and results reported as pg of uPA or PAI-1 per mg total
NAF protein.
PGE2
NAF and plasma samples were analyzed by immunoassay
for their PGE2 content as per the manufacturer's instruc-
tions (R&D Systems, Minneapolis, MN). The kit uses a
monoclonal antibody to PGE2 to competitively bind the
PGE2 in the standard or sample. Briefly, samples were
diluted in 100 μL assay buffer supplied by the manufac-
turer, pipetted into appropriate wells, incubated for
18–24 hrs at 4°C, washed, substrate solution added, fol-
lowed by 1 hr incubation, and absorbance measured at
405 nm.
A standard curve was prepared using serial dilutions of
PGE2. A linear regression equation was created from
standards of known PGE2 concentration, and PGE2 con-
centrations of unknown samples fit to the standard curve
regression equation, corrected for aliquot volume and
expressed as nanograms of PGE2/mL of original sample.
Whenever possible, NAF and plasma samples were run in
duplicate and the average of the two values was reported.
The goodness of fit of the standard curve, R2, for NAF sam-
ples was 0.999. The goodness of fit was similar for the
plasma samples.
Celecoxib
Celecoxib was analyzed in plasma using a modification of
the technique of Schonberger et al. [21] by combining 250
μL aliquots of plasma with an equal volume of distilled
water and adding 500 μL ethanol to precipitate the pro-
tein. Spiked plasma samples were prepared by combining
250 μL blank plasma with 250 μl distilled water, 20 μL of
10 ppm celecoxib in ethanol and 480 μL of ethanol. Sam-
ples were vortexed and then centrifuged at 13,000 rpm for
5 min. A 500 μL aliquot of the supernatant was combined
with 1.5 mL distilled water and applied to a Waters 3 mL
C18 Sep-Pac-Vac disposable cleanup column (Waters, Mil-
ford, MA) which was preconditioned with 2 mL methanol
and then 2 mL distilled water. Cleanup columns were
washed with 2 mL distilled water and vacuum dried for 15
minutes. Celecoxib was eluted with 4 mL methanol and
the sample eluants taken to dryness. Samples were recon-
stituted in 1.0 mL methanol:water (80:20) for HPLC anal-
ysis.
HPLC analysis was performed on an Hitachi HPLC system
(Hitachi Instruments, Inc., San Jose, CA) which consisted
of an L7100 pump, with an L7200 autosampler (20 ul
injected), and fluorescence detection with an L7480 fluo-
rescence detector (excitation 240 nm, emission 380 nm).
The system was controlled, data acquired and processed
using an Hitachi D-7000 data acquisition package with
Concert Chrom software on a microcomputer. A Phenom-
enex Hypersil BDS C18 analytical column (250 × 4.6 mm,
5 um) (Phenomenex, Torrence, CA) and a Phenomenex
Securityguard C18 precolumn with a mobile phase of ace-BMC Cancer 2008, 8:298 http://www.biomedcentral.com/1471-2407/8/298
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tonitrile:water (70:30) was used at a flow rate of 1 mL/
min. Celecoxib was kindly provided by Pfizer Corpora-
tion, New York, NY. A primary standard of celecoxib
(2,000 ppm) was prepared in acetonitrile. Working stand-
ards (100, 200, 500 ppb) were prepared in metha-
nol:water (80:20). Plasma samples spiked with celecoxib
had recoveries greater than 95%.
Toxicity
Among women taking celecoxib 200 mg bid, two subjects
experienced side effects (one nausea, the second a cough),
with both resolving spontaneously. There were no drop-
outs in the 200 mg bid group. Among women enrolled in
the 400 mg bid group, 11 experienced side effects from
celecoxib, four of whom dropped out. Of the four who
dropped out, the side effects (edema in two, diarrhea in
one, and heart palpitations in one) resolved shortly after
stopping celecoxib. Among the remaining seven subjects,
the side effects: diarrhea, nausea, rash, altered taste, uri-
nary urgency, sweating, and muscle tension, all resolved
spontaneously.
Statistical analysis
Median values of continuous variables were computed for
the various groups of subjects. Due to the potential non-
normality of the data, ranking procedures were used for
all analyses with continuous variables. The Wilcoxon
Rank Sum Test was used to compare independent groups.
Examples of these comparisons include comparing pre-
and postmenopausal women. The Wilcoxon Signed Rank
Test was used to make within group comparisons such as
comparing pre treatment to post treatment.
We are interested in the change which occurs from pre to
post treatment. Because of the potential skewness of the
data, we report medians rather than means. The delta (Δ)
reported in Table 2 is the median of the post – pre treat-
ment differences. It should be noted that the median of
these differences is seldom equal to the difference (post –
pre) in the medians. Thus, the Δ reported in Table 2 could
be negative and the difference in the medians positive.
Table 2: Median concentrations in NAF of uPA and PAI-1 (pg/mg), PGE2 (ng/mL) and in plasma of celecoxib (ng/mL) based on 
celecoxib dose and menopausal status1
Dose N Baseline After Tx Δ P value Celecoxib
200 mg bid2
uPA
Overall 9 422.0 375.2 -19.6 0.10 346.0
Premen 2 133.6 130.1 -3.5 0.50 231.8
Postmen 7 645.1 402.4 -57.0 0.22 728.2
PAI-1
Overall 8 709.0 194.4 -26.7 0.56 288.1
Premen 2 2672 1821 -850.8 0.99 231.8
Postmen 6 709.0 194.4 -26.7 0.99 479.1
PGE2
Overall 9 8.71 13.34 -1.04 0.91 346.0
Premen 2 25.45 25.96 0.52 0.99 231.8
Postmen 7 8.71 9.80 -1.04 0.81 728.2
400 mg bid2
uPA
Overall 11 372.6 321.6 22.0 0.46 184.0
Premen 5 372.6 321.6 11.0 0.99 0
Postmen 6 409.1 382.4 28.2 0.31 1141.8
PAI-1
Overall 5 2401 827.8 0 0.62 156.8
Premen 1 281.6 344.7 63.1 - 0
Postmen 4 2416 1437 -801.7 0.50 789.9
PGE2
Overall 11 12.32 13.45 -1.77 0.96 184.2
Premen 5 12.32 51.24 21.95 0.31 0
Postmen 6 14.79 13.22 -6.41 0.16 1141.8
1: N: sample size; NAF: nipple aspirate fluid. NS: not significant. Units reflect pg uPA or PAI-1/mg total protein. Δ reflects the median of the change 
measured in each subject (after treatment value – before treatment value) due to treatment. Celecoxib level is from plasma collected after 
treatment.
2: Not all NAF samples were sufficient to analyze all proteins; bid: twice daily; premen: premenopausal; postmen: postmenopausalBMC Cancer 2008, 8:298 http://www.biomedcentral.com/1471-2407/8/298
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Results
Subjects
Of 42 women evaluated, 17 took celecoxib 200 mg bid
and 25 celecoxib 400 mg bid . Matched (pre and post
treatment) plasma was available from all subjects.
Matched NAF was available for analysis from approxi-
mately half of the subjects. All subjects reported that they
took over 80% of the pills they were administered (Table
1).
Celecoxib concentrations in ng/mL
At the end of treatment, celecoxib was detectable in the
plasma of 14 of 17 participants (82%) in the 200 mg
group, and 19 of 25 participants (76%) in the 400 mg
group. The limit of detection of the assay was 100 ng/mL.
Of samples in which celecoxib was detectable, values
ranged from 117.6 to 2281.2 ng/mL in the 200 mg group
and from 156.8 to 16403.1 ng/mL in the 400 mg group.
Levels trended (p = 0.12) higher in women taking 400 mg
(median 1025.0 ng/mL) compared to 200 mg bid
(median 227.3 ng/mL), and in post- (534.6 ng/mL) com-
pared to premenopausal (227.3 ng/mL) women (p =
0.13).
uPA levels in postmenopausal women increase, while PAI-
1 and PGE2 decrease, after treatment with high dose 
celecoxib
We first evaluated the change in uPA, PAI-1 and PGE2 con-
centration in the NAF of each participant after low and
high dose celecoxib administration (Table 2). The delta
(Δ) in Table 2 represents the median change due to
celecoxib intervention. uPA trended downward with low
dose and upward with high dose treatment. PAI-1 trended
downward at both celecoxib doses. PGE2 concentrations
also tended to decrease overall at both doses of celecoxib
but the values measured in premenopausal women were
slightly increased. This coincided with relatively low
plasma concentrations of celecoxib. The changes in uPA,
PAI-1 and PGE2 were not significant at either dose for pre-
or postmenopausal women.
We next evaluated the change in plasma uPA and PGE2
concentration after low and high dose celecoxib adminis-
tration (Table 3). PAI-1 was not evaluated in plasma due
to inadequate samples available. Similar to NAF, uPA lev-
els in plasma trended downward with low dose and
upward with high dose treatment. Plasma PGE2 changed
little after treatment, with a small move upward with low
dose and downward move with high dose therapy. The
change in neither uPA nor PGE2 was significant for either
pre- or postmenopausal women.
Effect of circulating celecoxib concentrations on 
biomarker change
Considering subjects in both dosage groups, there was an
inverse correlation between celecoxib concentration and
change in NAF PGE2 (r = -.42, p = .06, n = 20) and plasma
uPA (r = .38, p = .012, n = 42) post treatment, which was
not observed for the other markers. There were no signifi-
cant associations between uPA, PAI-1 or PGE2 in NAF or
plasma and celecoxib concentration in women receiving
low dose celecoxib. In women taking the higher dose,
both PAI-1 (r = -.97, p = .0048, n = 5) and PGE2 (r = -.69,
p = .019, n = 11) in NAF and uPA in plasma (r = .45, p =
.023, n = 25) were correlated with celecoxib concentration
(Figure 1).
Discussion
We carried out experiments to investigate whether the
COX-2 inhibitor celecoxib at a dose of either 200 mg bid
or 400 mg bid could significantly affect endogenous uPA,
PAI-1 or PGE2 production in women at increased risk for
breast cancer. The same NAF and plasma samples were
used to measure all three markers so that we could deter-
mine celecoxib's coordinate effect on them. This study
builds on our initial study, which found that celecoxib
400 mg bid decreased PGE2 levels in NAF and/or plasma
in women with newly diagnosed breast cancer and in high
risk women [16].
We previously observed that uPA and PAI-1 are concen-
trated in NAF compared to plasma [22]. This fact, as well
as the fact that NAF is breast specific, undiluted by the
contribution from other organs, suggests that it may be a
better physiologic fluid than plasma to identify breast
cancer biomarkers.
uPA expression trended downward among women receiv-
ing the lower celecoxib dose and upward among those
receiving the higher dose, suggesting a dose-dependent
effect of the medication. Sample size may have limited
our ability to detect a significant effect. The different uPA
response was more noted in post- than in premenopausal
women, in whom celecoxib concentrations tended to be
higher. Similarly, we previously observed that high (but
not low) dose celecoxib significantly decreased PGE2 lev-
Table 1: Demographics
Celecoxib Dose
200 mg twice daily
NAF (plasma)
400 mg twice daily
NAF (plasma)
Samples 9 (17) 11 (25)
Age (years)
Median 46 (51) 51 (50)
Range 23–67 (23–68) 30–68 (30–81)
Menopause
Pre 2 (4) 5 (11)
Post 7 (13) 6 (14)BMC Cancer 2008, 8:298 http://www.biomedcentral.com/1471-2407/8/298
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els in post- but not premenopausal women, in whom
higher circulating celecoxib levels were noted [16]. In the
current study a similar trend was noted for PGE2. Sample
size may have limited our ability to detect a significant
effect.
Mice prone to the development of intestinal adenomas
that were made deficient in uPA were found to upregulate
COX-2 expression [23]. It has been shown that PAs gener-
ate endogenous angiogenesis inhibitors, and mice with
tumors that overexpressed uPA demonstrated tumor
growth inhibition, fewer lung metastases and prolonged
survival compared to controls [8]. There is evidence that
PAI-1, an inhibitor of uPA, may promote angiogenesis
[10]. It was found that celecoxib was more effective than
the combination of celecoxib plus the PA inhibitor amilo-
ride in reducing the number of pulmonary metastases,
with metastases suppressed by 67% with amiloride alone,
98% with celecoxib alone and 81% with the combined
regimen. In our own subjects, medication dose provided
hints as to the effect of celecoxib, but the effect was
masked by individual differences in celecoxib metabo-
lism. On the other hand, evaluating the circulating level of
celecoxib demonstrated the effect of the agent, and con-
sistent with preclinical reports discussed above, NAF lev-
els of PAI-1 and PGE2 decreased in relation to increasing
celecoxib concentrations, while uPA plasma levels
increased in relation to increased circulating celecoxib
(Figure 1).
Conclusion
Patients receiving celecoxib 200 mg bid demonstrated
decreased uPA concentrations in NAF and plasma whereas
patients receiving celecoxib 400 mg bid demonstrated
increased concentrations of uPA in both NAF and plasma.
PAI-1 was more decreased in the NAF of patients receiving
the 200 compared to the 400 mg bid celecoxib dose. PGE2
concentrations trended lower in both NAF and plasma
after celecoxib treatment. PAI-1 and PGE2 decreased in
NAF and uPA increased in plasma in relation to the circu-
lating level of celecoxib, which may better reflect the
action of the agent than dosage, since individuals metab-
olize celecoxib at different rates. These findings are con-
sistent with animal studies which suggest that, unlike in
subjects with invasive breast cancer (in whom high levels
of uPA are associated with a poor prognosis [24]), in high
risk women the upregulation of uPA (in association with
downregulation of PAI-1 and PGE2) may have a breast
cancer chemopreventive effect.
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Table 3: Median concentrations in plasma of uPA (pg/mL), PGE2 (ng/mL) and celecoxib (ng/mL) based on celecoxib dose and 
menopausal status1
Dose N Baseline After Tx Δ P Value Celecoxib
200 mg bid2
uPA
Overall 17 941.4 955.0 -20.7 0.85 233.7
Premen 4 886.9 1031.8 36.0 0.62 195.3
Postmen 13 994.0 945.6 -20.7 0.64 233.7
PGE2
Overall 17 0.209 0.206 0.005 0.96 233.7
Premen 4 0.244 0.221 0.100 0.99 0
Postmen 13 0.204 0.195 0.005 0.84 233.7
400 mg bid2
uPA
Overall 25 908.3 910.7 17.5 0.8 696.0
Premen 11 864.9 821.0 17.5 0.8 227.3
Postmen 14 1036.1 992.4 7.9 0.7 1024.9
PGE2
Overall 25 0.280 0.203 -0.009 0.93 696.0
Premen 11 0.375 0.366 -0.001 0.77 227.2
Postmen 14 0.280 0.175 -0.023 0.90 1025.0
1: N: sample size; NAF: nipple aspirate fluid. Units reflect pg uPA/mL plasma volume. Δ uPA reflects the median of the change measured in each 
subject (after treatment value – before treatment value) due to treatment. Celecoxib level is from plasma collected after treatment.
2: bid: twice daily; premen: premenopausal; postmen: postmenopausal.BMC Cancer 2008, 8:298 http://www.biomedcentral.com/1471-2407/8/298
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